Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Faeth Therapeutics, Inc.NASDAQ: FTH
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $4.48M rose 1598.1% year over year, ahead of the +869.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 65.2% from the prior quarter. Over 3 fiscal years it compounded at -39.7% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1598.1% holds above the trailing-twelve-month pace of +869.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.27M USD
- Year-over-year change
- -59.4%
- 4-year CAGR
- -31.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.27M | -59.4% |
| FY2024 | 2024-12-31 | 3.14M | -29.6% |
| FY2023 | 2023-12-31 | 4.45M | -23.4% |
| FY2022 | 2022-12-31 | 5.81M | +2.7% |
| FY2021 | 2021-12-31 | 5.66M | — |
Stock-Based Compensation vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's LTM Jun 2026 stock-based compensation of $17.93M is the 6th largest of the 10 companies compared; the peer median is $10.08M.
- Its year-over-year change of +869.7% is the highest of 10, against a peer median of -13.7%.
- Over three fiscal years its annual growth of -39.7% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $58.58M | +109.9% | +22.9% | — | |
| LTM Jun 2026 | $48.31M | -34.7% | +3.6% | 466.8% | |
| LTM Mar 2026 | $38.79M | +1.8% | +32.7% | 179.5% | |
| LTM Mar 2026 | $37.68M | +13.4% | +12.1% | 52.6% | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
| LTM Jun 2026 | $17.93M | +869.7% | -39.7% | — | |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $6.81M | -13.7% | -16.3% | 3.0% | |
| LTM Mar 2026 | $4.33M | -45.8% | +38.8% | — | |
| Peer median (excluding FTH) | $10.08M | -13.7% | +15.9% | 52.6% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Depreciation & Amortization | 685K | 1.35M | 1.35M | 1.32M | 139K |
| Deferred Income Tax | 19K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.66M | 5.81M | 4.45M | 3.14M | 1.27M |
| Change in Working Capital | 117K | 1.01M | (4.33M) | (489K) | (1.59M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.43M) | 2.02M | (2.33M) | (445K) | 233K |
| Other Working Capital | 1.54M | (1.01M) | (2M) | (44K) | (1.83M) |
| Other Non-Cash Items | 57K | 1.4M | 603K | 1.52M | 811K |
| Operating Cash Flow | (30.26M) | (39.03M) | (32.02M) | (24.67M) | (20.45M) |
| Capital Expenditures | (2.03M) | (321K) | (180K) | (146K) | (16K) |
| Acquisitions (Net) | 318K | 15K | 166K | 0 | 250K |
| Purchases of Investments | (183.67M) | (46.87M) | (21.15M) | (44.6M) | (25.16M) |
| Sales of Investments | 42.26M | 97.12M | 59.58M | 67.18M | 44.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.12M) | 49.95M | 38.41M | 22.44M | 19.77M |
| Debt Repayment | (255K) | (629K) | (761K) | (811K) | (648K) |
| Common Stock Issued | 140.59M | 342K | 48K | 34K | 7K |
| Common Stock Repurchased | 0 | 0 | (10.38M) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 109K | 0 | (76K) | (10K) | (3K) |
| Financing Cash Flow | 163.94M | (287K) | (11.17M) | (787K) | (645K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.44M) | 10.64M | (4.78M) | (3.02M) | (1.33M) |
| Free Cash Flow | (32.29M) | (39.35M) | (32.2M) | (24.82M) | (20.47M) |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.